Veracity Capital LLC Sells 140 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Veracity Capital LLC reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.4% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,672 shares of the biopharmaceutical company’s stock after selling 140 shares during the period. Regeneron Pharmaceuticals makes up 2.3% of Veracity Capital LLC’s investment portfolio, making the stock its 7th largest holding. Veracity Capital LLC’s holdings in Regeneron Pharmaceuticals were worth $5,963,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of REGN. Park Avenue Securities LLC increased its position in shares of Regeneron Pharmaceuticals by 9.2% during the first quarter. Park Avenue Securities LLC now owns 1,671 shares of the biopharmaceutical company’s stock worth $1,609,000 after acquiring an additional 141 shares in the last quarter. International Assets Investment Management LLC increased its holdings in Regeneron Pharmaceuticals by 9.4% during the 1st quarter. International Assets Investment Management LLC now owns 736 shares of the biopharmaceutical company’s stock worth $713,000 after purchasing an additional 63 shares in the last quarter. Ballentine Partners LLC raised its stake in shares of Regeneron Pharmaceuticals by 37.7% in the first quarter. Ballentine Partners LLC now owns 1,040 shares of the biopharmaceutical company’s stock worth $1,001,000 after purchasing an additional 285 shares during the last quarter. Northwest Investment Counselors LLC bought a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $177,000. Finally, Traynor Capital Management Inc. boosted its position in shares of Regeneron Pharmaceuticals by 4.7% during the first quarter. Traynor Capital Management Inc. now owns 19,746 shares of the biopharmaceutical company’s stock valued at $19,005,000 after buying an additional 878 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the sale, the vice president now directly owns 4,204 shares in the company, valued at $4,498,280. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.48% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Wells Fargo & Company reissued an “overweight” rating and issued a $1,200.00 price target on shares of Regeneron Pharmaceuticals in a research report on Monday, September 23rd. Morgan Stanley lowered their target price on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. JPMorgan Chase & Co. boosted their price target on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. TD Cowen increased their price objective on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Finally, StockNews.com raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, October 9th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, sixteen have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $1,116.00.

Regeneron Pharmaceuticals Stock Down 0.8 %

Regeneron Pharmaceuticals stock opened at $990.68 on Friday. The firm has a 50 day simple moving average of $1,109.58 and a 200 day simple moving average of $1,040.38. The firm has a market capitalization of $109.16 billion, a price-to-earnings ratio of 29.27, a P/E/G ratio of 3.45 and a beta of 0.12. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a 1-year low of $769.19 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. During the same period in the prior year, the firm posted $8.79 earnings per share. The company’s revenue for the quarter was up 12.3% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.85 earnings per share for the current year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.